Company Profile For Celgene Corporation

Celgene Corporation is an integrated biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is involved in research in several scientific areas that may deliver therapies, targeting areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmunity and placental cell, including stem and progenitor cell, research. The drug and cell therapies it develops are designed to treat life-threatening diseases or chronic debilitating conditions. The Company’s commercial stage products include REVLIMID, THALOMID (inclusive of Thalidomide Pharmion), VIDAZA, ALKERAN and FOCALIN. On March 7, 2008, it acquired Pharmion Corporation, a biopharmaceutical company that acquired, developed and commercialized products for the treatment of hematology and oncology patients.

BRIEF: For the nine months ended 30 September 2009, Celgene Corporation's revenues increased 19% to $1.93B. Net income totaled $522.5M vs. a loss of $1.38B. Revenues reflect higher income generated from net product sales and an increase in royalty revenue. Net income reflects the absence of acquired in-process research & development, lower cost of goods sold and a decrease in equity in losses of affiliated companies.